Welcome to our dedicated page for Precigen SEC filings (Ticker: PGEN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Precigen, Inc. filings document the company’s biopharmaceutical operations, commercial product disclosures, governance matters, and capital structure. Form 8-K reports cover financial results, PAPZIMEOS business updates, investor presentations, commercial supply arrangements, and financing agreements tied to the company’s transition into commercial-stage operations.
Precigen’s proxy materials describe board elections, auditor ratification, executive compensation votes, and equity incentive plan matters. Other filings disclose its Nasdaq-listed common stock, preferred-stock conversion activity, senior secured debt arrangements, material agreements, risk factors, and corporate governance controls relevant to a public precision-medicine company.
Point72 Asset Management and affiliated filers report shared beneficial ownership of 6,741,861 shares of Precigen, Inc. Common Stock, representing 1.9% of the class as of March 31, 2026. The amount reported includes 97,500 shares issuable upon exercise of call options. The statement is filed on behalf of Point72 Asset Management, Point72 Capital Advisors, Inc., and Steven A. Cohen; all three report no direct sole ownership and disclose shared voting and dispositive power over the 6,741,861 shares.
Precigen, Inc. reported sharply improved results for the quarter ended March 31, 2026, driven by the US launch of PAPZIMEOS for recurrent respiratory papillomatosis. Total revenues were $23.3 million, up from $1.3 million a year earlier, with $21.6 million from PAPZIMEOS sales.
The company’s net loss narrowed to $7.9 million, or $0.02 per share, compared with a net loss of $54.2 million, or $0.18 per share, in the prior-year quarter. Management highlighted approximately 400 patients enrolled in the PAPZIMEOS hub and reiterated that current cash, investments and expected PAPZIMEOS cash collections are anticipated to fund operations through cash flow break-even by the end of 2026.
Precigen, Inc. reported a sharp shift toward commercial operations in the quarter ended March 31, 2026, driven by sales of its first approved product, Papzimeos for recurrent respiratory papillomatosis. Total revenue rose to $23.3 million from $1.3 million a year earlier, including $21.6 million from Papzimeos and $1.7 million from Exemplar’s products and services.
Operating loss narrowed to $6.0 million from $22.6 million, and net loss improved to $7.9 million from $54.2 million, aided by the absence of prior-period warrant fair value charges. However, operating activities used $43.8 million of cash in the quarter, reflecting working capital buildup, inventory growth and higher selling, general and administrative expenses of $21.0 million to support the Papzimeos launch.
At March 31, 2026, Precigen held $56.7 million in cash, cash equivalents and investments and had $93.5 million in long‑term debt under a five‑year Pharmakon‑managed loan facility. The company emphasizes that continued commercialization of Papzimeos is key to its path toward profitability.
Precigen, Inc. is holding its 2026 virtual Annual Meeting on June 18, 2026, with April 17, 2026 as the record date. Shareholders will vote on electing nine directors, ratifying Deloitte & Touche LLP, approving 2025 executive compensation on an advisory basis, and amending the 2023 Omnibus Incentive Plan to increase the shares available for awards by 7 million.
Each share of common stock outstanding as of the record date is entitled to one vote, with 356,510,977 shares outstanding at that time. The proxy also reviews corporate governance practices, director and executive pay, beneficial ownership, auditor fees and the company’s 2025 performance, including FDA approval and initial launch of Papzimeos for recurrent respiratory papillomatosis.
PRECIGEN, INC. Chief Legal Officer Donald P. Lehr received new equity awards in the form of restricted stock units and stock options. On April 20, 2026, he was granted 107,000 RSUs, each representing one share of common stock, and 358,000 stock options with a $4.11 exercise price.
The RSUs vest 25% on May 23, 2027 and then in equal six‑month installments over three years. The options vest 25% on the same May 23, 2027 date, followed by equal monthly installments for three years, and expire on April 20, 2036. These awards are compensation-related grants rather than open‑market purchases.
PRECIGEN, INC. reported that President and CEO Helen Sabzevari received new equity awards. She was granted 410,000 Restricted Stock Units, each representing one share of common stock, and options on 1,366,000 shares of common stock at an exercise price of $4.11 per share.
The options vest 25% on May 23, 2027 and then in equal monthly installments over three years, while the RSUs vest 25% on the same date and then in equal six‑month installments over three years. No shares were sold in these transactions.
PRECIGEN, INC. Chief Operating Officer Rutul R. Shah received new equity awards as part of his compensation. He was granted 118,000 restricted stock units, each representing the right to receive one share of Precigen common stock. He was also granted options on 395,000 shares of common stock at an exercise price of $4.11 per share.
The options vest 25% on May 23, 2027 and then in equal monthly installments for three years. The RSUs vest 25% on May 23, 2027 and then in equal six-month installments for three years, aligning his incentives with the company’s longer-term performance.
Precigen, Inc. reported that Chief Commercial Officer Phil Tennant received new equity awards. On April 20, 2026, he was granted 115,000 restricted stock units, each representing the right to receive one share of Precigen common stock. He was also granted 385,000 stock options with an exercise price of $4.11 per share, expiring on April 20, 2036.
The options vest 25% on May 23, 2027 and then in equal monthly installments for three years. The RSUs vest 25% on May 23, 2027 and then in equal six-month installments for three years. After these grants, Tennant holds 115,000 RSUs and options covering 385,000 shares, all as direct ownership.
Precigen, Inc.’s Chief Financial Officer Harry Thomasian Jr. reported compensation-related equity grants. He received 120,000 Restricted Stock Units, each representing one share of Precigen common stock, and options on 399,000 shares of common stock at an exercise price of $4.11 per share.
The options vest 25% on May 23, 2027, then in equal monthly installments for three years. The RSUs vest 25% on May 23, 2027, then in equal six‑month installments for three years. The filing shows no open‑market purchases or sales, only awards granted.